NYMX Stock Overview
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally.
Nymox Pharmaceutical Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$0.46|
|52 Week High||US$2.27|
|52 Week Low||US$0.35|
|1 Month Change||9.83%|
|3 Month Change||-64.52%|
|1 Year Change||-72.04%|
|3 Year Change||-67.28%|
|5 Year Change||-88.99%|
|Change since IPO||-92.73%|
Recent News & Updates
|NYMX||US Biotechs||US Market|
Return vs Industry: NYMX underperformed the US Biotechs industry which returned -24.3% over the past year.
Return vs Market: NYMX underperformed the US Market which returned -18.4% over the past year.
|NYMX Average Weekly Movement||22.1%|
|Biotechs Industry Average Movement||13.2%|
|Market Average Movement||8.1%|
|10% most volatile stocks in US Market||16.6%|
|10% least volatile stocks in US Market||3.2%|
Stable Share Price: NYMX is more volatile than 90% of US stocks over the past 3 months, typically moving +/- 22% a week.
Volatility Over Time: NYMX's weekly volatility has increased from 16% to 22% over the past year.
About the Company
Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products.
Nymox Pharmaceutical Fundamentals Summary
|NYMX fundamental statistics|
Is NYMX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|NYMX income statement (TTM)|
|Cost of Revenue||US$0|
Last Reported Earnings
Mar 31, 2022
Next Earnings Date
|Earnings per share (EPS)||-0.17|
|Net Profit Margin||0.00%|
How did NYMX perform over the long term?See historical performance and comparison
Is NYMX undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 2/6
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for NYMX?
Other financial metrics that can be useful for relative valuation.
|What is NYMX's n/a Ratio?|
Price to Book Ratio vs Peers
How does NYMX's PB Ratio compare to its peers?
|NYMX PB Ratio vs Peers|
|Company||PB||Estimated Growth||Market Cap|
AIKI AIkido Pharma
INFI Infinity Pharmaceuticals
ENZN Enzon Pharmaceuticals
AURX Nuo Therapeutics
NYMX Nymox Pharmaceutical
Price-To-Book vs Peers: NYMX is good value based on its Price-To-Book Ratio (-29.2x) compared to the peer average (22.7x).
Price to Earnings Ratio vs Industry
How does NYMX's PE Ratio compare vs other companies in the US Biotechs Industry?
Price-To-Book vs Industry: NYMX is good value based on its Price-To-Book Ratio (-29.2x) compared to the US Biotechs industry average (1.6x)
Price to Book Ratio vs Fair Ratio
What is NYMX's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PB Ratio||-30x|
|Fair PB Ratio||n/a|
Price-To-Book vs Fair Ratio: Insufficient data to calculate NYMX's Price-To-Book Fair Ratio for valuation analysis.
Share Price vs Fair Value
What is the Fair Price of NYMX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate NYMX's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate NYMX's fair value for valuation analysis.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate NYMX's PEG Ratio to determine if it is good value.
Discover undervalued companies
- Take a look at our analysis of NYMX's management and see if the CEO's compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How is Nymox Pharmaceutical forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Future Growth Score0/6
Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Nymox Pharmaceutical has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
Discover growth companies
- Take a look at our analysis of NYMX’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
How has Nymox Pharmaceutical performed over the past 5 years?
Past Performance Score0/6
Past Performance Score 0/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: NYMX is currently unprofitable.
Growing Profit Margin: NYMX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: NYMX is unprofitable, and losses have increased over the past 5 years at a rate of 0.5% per year.
Accelerating Growth: Unable to compare NYMX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: NYMX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (96.9%).
Return on Equity
High ROE: NYMX's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.
Discover strong past performing companies
How is Nymox Pharmaceutical's financial position?
Financial Health Score1/6
Financial Health Score 1/6
Short Term Liabilities
Long Term Liabilities
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: NYMX has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Long Term Liabilities: NYMX has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Debt to Equity History and Analysis
Debt Level: NYMX is debt free.
Reducing Debt: NYMX's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: NYMX has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: NYMX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 14.9% each year
Discover healthy companies
What is Nymox Pharmaceutical current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate NYMX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate NYMX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if NYMX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if NYMX's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as NYMX has not reported any payouts.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Paul Averback (70 yo)
Dr. Paul Averback, M.D., D A.B.P., has been the President of Nymox Pharmaceutical Corporation since September 1995 and serves as its Chief Executive Officer. Dr. Averback is the Founder of Nymox Pharmaceut...
CEO Compensation Analysis
Compensation vs Market: Paul's total compensation ($USD1.41M) is above average for companies of similar size in the US market ($USD749.40K).
Compensation vs Earnings: Paul's compensation has increased whilst the company is unprofitable.
Experienced Management: NYMX's management team is seasoned and experienced (7.2 years average tenure).
Experienced Board: NYMX's board of directors are seasoned and experienced ( 16 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: NYMX insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 9.6%.
Nymox Pharmaceutical Corporation's employee growth, exchange listings and data sources
- Name: Nymox Pharmaceutical Corporation
- Ticker: NYMX
- Exchange: NasdaqCM
- Founded: 1989
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$40.509m
- Shares outstanding: 90.28m
- Website: https://nymox.com
- Nymox Pharmaceutical Corporation
- Bay & Deveaux Streets
- 2nd Floor
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/06/27 00:00|
|End of Day Share Price||2022/06/27 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.